BIODANE PHARMA A/S: Financial statements 2020
CVR: 28310102
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
BIODANE PHARMA A/S (CVR 28310102) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 1,628,847 and a net result of DKK 499,535 compared with DKK 256,752 the year before. That is an increase of 8% compared with the year before. Equity in the 2020 report amounted to DKK 2,158,515. The solvency ratio was 89%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,628,847
- Profit/Loss
- DKK 499,535
- Equity
- DKK 2,158,515
- Total Assets
- DKK 2,426,633
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 1.6 mio. | 500 t. | 2.2 mio. | 1 |
| 2019 | - | 1.5 mio. | 257 t. | 1.7 mio. | 1 |
| 2018 | - | 1 mio. | -467 t. | 1.4 mio. | 1 |
| 2017 | - | 968 t. | 103 t. | 1.9 mio. | 1 |
| 2016 | - | 747 t. | 33 t. | 767 t. | 1 |
Official annual report
How creditworthy is BIODANE PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
BIODANE PHARMA A/S has published its annual report for 2019. Gross profit came to DKK 1,508,453, and the net result was DKK 256,752.
About BIODANE PHARMA A/S
BIODANE PHARMA A/S is a Danish company of the type Aktieselskab based in Gesten, founded in 2004. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named BIODANE PHARMA ApS and BIOFIBER TØRRING ApS. The management consists of Gunner Kreutzer Jakobsen. The board consists of Peter Gæmelke (chair), Flemming Torben Heden Knudsen, Gunner Kreutzer Jakobsen and Rasmus Juhl Rasmussen. The company is owned by BIODAN A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 2,534,166 and a net result of DKK 182,862 compared with DKK 1,651,356 the year before. Equity in the 2025 report amounted to DKK 2,505,002.